Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection

Research output: Contribution to journalReview article

Abstract

Introduction: Cytomegalovirus (CMV) still causes significant morbidity and mortality in patients given allogeneic hematopoietic stem cell transplantation (HSCT). Despite effective pharmacotherapy, potentially life-threatening CMV disease occurs nowadays in up to 10% of HSCT recipients; moreover, routinely used anti-CMV agents have been shown to be associated with morbidity. Areas covered: This review examines different issues related to diagnosis and management of CMV infection in HSCT recipients, paying particular attention to the monitoring of CMV-specific immune recovery, approaches of adoptive cell therapy and new antiviral drugs. Expert commentary: Despite advances in diagnostic tests and treatment, there is still room for refining management of CMV in HSCT recipients. Immunological monitoring should be associated in the future to virological monitoring. The safety profile and efficacy of new anti-CMV agents should be compared with that of standard-of-care drugs. Donor-derived, pathogen-specific T cells adoptively transferred after transplantation could contribute to reduce the impact of CMV infection on patient’s outcome.

Original languageEnglish
Pages (from-to)1093-1105
Number of pages13
JournalExpert Review of Hematology
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Hematopoietic Stem Cells
Cytomegalovirus
Hematopoietic Stem Cell Transplantation
Transplants
Infection
Cytomegalovirus Infections
Morbidity
Immunologic Monitoring
Standard of Care
Cell- and Tissue-Based Therapy
Routine Diagnostic Tests
Antiviral Agents
Transplant Recipients
Transplantation
Tissue Donors
T-Lymphocytes
Safety
Drug Therapy
Mortality
Pharmaceutical Preparations

Keywords

  • adoptive T-cell therapy
  • anti-viral drugs
  • CMV infection
  • CMV vaccines
  • generation of CMV-specific T cells
  • immune monitoring
  • monitoring of CMV viral load

ASJC Scopus subject areas

  • Hematology

Cite this

Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection. / Locatelli, Franco; Bertaina, Alice; Bertaina, Valentina; Merli, Pietro.

In: Expert Review of Hematology, Vol. 9, No. 11, 01.11.2016, p. 1093-1105.

Research output: Contribution to journalReview article

@article{2d0bd1595cd24b40b7730ef823e8ee12,
title = "Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection",
abstract = "Introduction: Cytomegalovirus (CMV) still causes significant morbidity and mortality in patients given allogeneic hematopoietic stem cell transplantation (HSCT). Despite effective pharmacotherapy, potentially life-threatening CMV disease occurs nowadays in up to 10{\%} of HSCT recipients; moreover, routinely used anti-CMV agents have been shown to be associated with morbidity. Areas covered: This review examines different issues related to diagnosis and management of CMV infection in HSCT recipients, paying particular attention to the monitoring of CMV-specific immune recovery, approaches of adoptive cell therapy and new antiviral drugs. Expert commentary: Despite advances in diagnostic tests and treatment, there is still room for refining management of CMV in HSCT recipients. Immunological monitoring should be associated in the future to virological monitoring. The safety profile and efficacy of new anti-CMV agents should be compared with that of standard-of-care drugs. Donor-derived, pathogen-specific T cells adoptively transferred after transplantation could contribute to reduce the impact of CMV infection on patient’s outcome.",
keywords = "adoptive T-cell therapy, anti-viral drugs, CMV infection, CMV vaccines, generation of CMV-specific T cells, immune monitoring, monitoring of CMV viral load",
author = "Franco Locatelli and Alice Bertaina and Valentina Bertaina and Pietro Merli",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/17474086.2016.1242406",
language = "English",
volume = "9",
pages = "1093--1105",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection

AU - Locatelli, Franco

AU - Bertaina, Alice

AU - Bertaina, Valentina

AU - Merli, Pietro

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Cytomegalovirus (CMV) still causes significant morbidity and mortality in patients given allogeneic hematopoietic stem cell transplantation (HSCT). Despite effective pharmacotherapy, potentially life-threatening CMV disease occurs nowadays in up to 10% of HSCT recipients; moreover, routinely used anti-CMV agents have been shown to be associated with morbidity. Areas covered: This review examines different issues related to diagnosis and management of CMV infection in HSCT recipients, paying particular attention to the monitoring of CMV-specific immune recovery, approaches of adoptive cell therapy and new antiviral drugs. Expert commentary: Despite advances in diagnostic tests and treatment, there is still room for refining management of CMV in HSCT recipients. Immunological monitoring should be associated in the future to virological monitoring. The safety profile and efficacy of new anti-CMV agents should be compared with that of standard-of-care drugs. Donor-derived, pathogen-specific T cells adoptively transferred after transplantation could contribute to reduce the impact of CMV infection on patient’s outcome.

AB - Introduction: Cytomegalovirus (CMV) still causes significant morbidity and mortality in patients given allogeneic hematopoietic stem cell transplantation (HSCT). Despite effective pharmacotherapy, potentially life-threatening CMV disease occurs nowadays in up to 10% of HSCT recipients; moreover, routinely used anti-CMV agents have been shown to be associated with morbidity. Areas covered: This review examines different issues related to diagnosis and management of CMV infection in HSCT recipients, paying particular attention to the monitoring of CMV-specific immune recovery, approaches of adoptive cell therapy and new antiviral drugs. Expert commentary: Despite advances in diagnostic tests and treatment, there is still room for refining management of CMV in HSCT recipients. Immunological monitoring should be associated in the future to virological monitoring. The safety profile and efficacy of new anti-CMV agents should be compared with that of standard-of-care drugs. Donor-derived, pathogen-specific T cells adoptively transferred after transplantation could contribute to reduce the impact of CMV infection on patient’s outcome.

KW - adoptive T-cell therapy

KW - anti-viral drugs

KW - CMV infection

KW - CMV vaccines

KW - generation of CMV-specific T cells

KW - immune monitoring

KW - monitoring of CMV viral load

UR - http://www.scopus.com/inward/record.url?scp=84994021773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994021773&partnerID=8YFLogxK

U2 - 10.1080/17474086.2016.1242406

DO - 10.1080/17474086.2016.1242406

M3 - Review article

AN - SCOPUS:84994021773

VL - 9

SP - 1093

EP - 1105

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 11

ER -